Sciwind Biosciences rallies $70m Series C

Sciwind Biosciences Co, a developer of new therapies to treat metabolic disease, has secured $70 million in Series C financing.

12 October 2021•1 min read
Feature image
LinkedInXEmail
LinkedInXEmail

Related articles